The amyloid beta peptide is the major protein constituent of neuritic plaques in Alzheimer disease and
This study's primary aim was to evaluate the predictive value of Abeta40 blood levels in 2 independent cohorts of patients with stable CHD and assess the association of Abeta40 levels with incident CHD as well as the extent and progression of subclinical atherosclerosis.
METHODS
The present study involved 3 prospective and 2 case-control cohorts comprising 1,464 patients in hemodynamically stable condition who had been recruited in 3 European CV centers. First, patients undergoing diagnostic coronary angiography at the German Heart Centre in Munich (n ¼ 514) were consecutively recruited, as previously described (12) Athens cohort consisted of 556 consecutive patients age <75 years with creatinine levels of <2 mg/dl and stable CHD followed for a median of 61 months for MACE, as previously described (13) . The third prospective cohort consisted of young healthy subjects without clinically overt CHD who has arterial stiffness and Abeta40 levels evaluated at baseline and after a 5-year follow-up period (n ¼ 107). Finally, the peripheral atherosclerosis assessment cohort (n ¼ 394) was an ambulatory casecontrol cohort including patients without clinically overt CHD (control subjects; n ¼ 272) and patients with angiographically verified stable CHD (cases; n ¼ 122).
Patients with acute coronary syndrome (ACS), acute or chronic inflammatory conditions, infection, cancer, or stroke were not included in any of the cohorts. The local ethics committee of each university center approved the individual cohort studies, and patients provided written informed consent.
Blood samples for Abeta40 measurement were obtained as described in the Online Appendix. Plasma concentrations of high-sensitivity C-reactive protein (hsCRP) and high-sensitivity troponin T (hsTnT) were measured as previously described (12) . All laboratory measurements were performed by experienced staff blinded to clinical characteristics.
Peripheral atherosclerosis was assessed (14) , and a detailed description of the assessment is available in the Online Appendix.
STATISTICAL ANALYSIS. We used multivariable Cox proportional hazard models to examine the association 
RESULTS
The study design is depicted in Figure 1 . Associations between baseline characteristics of the 2 CHD cohorts in stable condition and quartiles of Abeta40 are shown in Table 1 . Age, hsCRP level, hsTnT level, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction (LVEF) progressively increased among Abeta40 quartiles. The incidence of CV death was significantly increased at the highest Abeta40 quartile compared with the other quartiles in both CHD cohorts in stable condition (p < 0.001) ( Table 1 , Figures 2A and 2B) . Similarly, the incidence of combined CV death and nonfatal acute myocardial infarction (MI) and incidence of the extended composite endpoint (CV death, nonfatal acute MI, rehospitalization due to ACS or myocardial revascularization) were also increased at the highest quartile of Abeta40 in both cohorts (p < 0.001) ( Table 1 ). Abeta40 remained a significant independent predictor for CV death and MACE after multivariable adjustment for age, sex, perform such an analysis in each cohort, we created a combined CHD cohort from the quartiles of the Munich and Athens cohorts (n ¼ 877). As described in the Online Appendix, we found no evidence of substantial heterogeneity between the 2 cohorts. Online Table 1 contains the descriptive characteristics of the combined total CHD cohort.
During the follow-up period of 4.4 years, patients experienced 77 CV deaths, 144 cumulative CV deaths and nonfatal acute MIs, and 257 MACE events in the total CHD cohort. In a univariate model, the cumulative incidence of CV death, as well as the secondary and extended composite endpoints, was significantly associated with increasing quartiles of Abeta40
( Figure 2C , Online Table 1 ). Abeta40 remained a significant predictor for CV death, as well as for secondary endpoints after multivariable adjustments for predictors of CV death (age, sex, LVEF, hsCRP level;
HR of the highest quartile vs. lowest quartile: 3.02;
95% CI: 1.51 to 6.04; p < 0.001) (Online Table 2 ). After additional adjustment for traditional risk factors over the best predictive model, these results did not substantially change.
Similar associations were observed in an analysis using Abeta40 as a standardized continuous variable (Online Table 3 ). As shown in Table 3 , Abeta40 significantly improved model calibration over the best predictive model for all 3 prospective endpoints (likelihood ratio test p < 0.001). Next, we addressed whether Abeta40 correctly reclassified risk of patients with stable CHD, thus predicting CV endpoints. Applying a category-free continuous NRI, category-based NRI for CV death (4.4-year risk categories <6%, 6% to 9%, and >9%), and IDI, we observed that Abeta40 correctly and significantly reclassified patients from lower to higher risk and vice versa better than age, sex, and LVEF ( Table 3) .
Abeta40 improved reclassification (continuous NRI)
even when hsCRP level was added to the adjustment model (NRI 36.7% for CV death; p < 0.001). Similarly, Abeta40 offered a significant IDI after adjustment for CV death predictors (p < 0.001). Similar results were obtained for CV death and nonfatal acute MI (secondary endpoint) and for the extended composite endpoint ( Table 3) . When the reclassification analysis was adjusted for cohort origin, these results did not change (data not shown). When reclassification analysis was performed for continuous standardized Abeta40, these results did not substantially change either (Online Table 4 ). Cross-sectional analysis of the Munich cohort also revealed that the incidence of angiographically confirmed CHD was positively associated with Abeta40 quartiles (Online Table 7 ). Abeta40 plasma concentration was higher in patients with CHD even Athens cohort
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The Kaplan-Meier survival analysis shows that patients belonging to the highest quartile of Abeta40 had the highest probability of death compared with patients in other quartiles in the Munich (A) (p < 0.001) and Athens (B) (p ¼ 0.002) cohorts, respectively. (C) The combined total cohort consists of all patients with CAD (n ¼ 877)
derived from the Munich and Athens cohorts. The Kaplan-Meier survival analysis shows that patients belonging to the highest quartile of Abeta40 had the highest probability of death compared with patients belonging to the other quartiles (p < 0.001). Abbreviations as in Figure 1 . Amyloid-Beta40 and Cardiovascular Death 909 in this association (17) . Given that arterial stiffness as an early marker of arteriosclerosis is closely associated with adverse CV events (18) , it is tempting to hypothesize that Abeta40 also may predict MACE in the general population. Tables 1 and 2. hsCRP, a well-established inflammatory biomarker. given that angiotensin receptor blockers may decrease Abeta40 concentrations in the brain (24, 26) , whereas furosemide, nitrendipine, and candesartan prevent oligomerization of Abeta40 in vitro (27) .
STUDY LIMITATIONS. Circulating levels of Abeta40 were not comparable among the study cohorts, probably due to methodological differences in storage conditions, which are known to affect Abeta40 stability and final concentration (28, 29) . This limitation does 
